Liquid biopsy: current technology and clinical applications

• Published in: Journal of hematology and oncology Vol. 15; no. 1; pp. 1 - 131
• Main Authors: Nikanjam, Mina, Kato, Shumei, Kurzrock, Razelle
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 12.09.2022; BioMed Central; BMC
• Subjects: Antibodies; Ascites; Biomarkers; Biopsy; Bisulfite; Blood; Body fluids; Cancer; Cancer therapies; Cerebrospinal fluid; cfDNA; Chemotherapy; CTC; ctDNA; Deoxyribonucleic acid; Diagnosis; DNA; DNA methylation; DNA sequencing; Exosomes; Genomes; Genomics; Hematology; Immune checkpoint; Immune system; Immunotherapy; Invasiveness; Liquid biopsy; Lung cancer; Lymphocytes T; Medical research; Medicine, Experimental; Metastases; Metastasis; Methylation; Mutation; Nanoparticles; Nucleotide sequencing; Oncology; Patients; Polymerase chain reaction; Precision medicine; Prostate; Proteins; Review; RNA; Sulfites; T cells; Technology application; Therapeutic applications; Tumor cells; Tumors; Whole genome sequencing
• ISSN: 1756-8722; 1756-8722
• DOI: 10.1186/s13045-022-01351-y

Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs) can be isolated from the blood and other body fluids. This review will focus on current technologies and clinical applications for liquid biopsies. ctDNA/cfDNA has been isolated and analyzed using many techniques, e.g., droplet digital polymerase chain reaction, beads, emulsion, amplification, and magnetics (BEAMing), tagged-amplicon deep sequencing (TAm-Seq), cancer personalized profiling by deep sequencing (CAPP-Seq), whole genome bisulfite sequencing (WGBS-Seq), whole exome sequencing (WES), and whole genome sequencing (WGS). CTCs have been isolated using biomarker-based cell capture, and positive or negative enrichment based on biophysical and other properties. ctDNA/cfDNA and CTCs are being exploited in a variety of clinical applications: differentiating unique immune checkpoint blockade response patterns using serial samples; predicting immune checkpoint blockade response based on baseline liquid biopsy characteristics; predicting response and resistance to targeted therapy and chemotherapy as well as immunotherapy, including CAR-T cells, based on serial sampling; assessing shed DNA from multiple metastatic sites; assessing potentially actionable alterations; analyzing prognosis and tumor burden, including after surgery; interrogating difficult-to biopsy tumors; and detecting cancer at early stages. The latter can be limited by the small amounts of tumor-derived components shed into the circulation; furthermore, cfDNA assessment in all cancers can be confounded by clonal hematopoeisis of indeterminate potential, especially in the elderly. CTCs can be technically more difficult to isolate that cfDNA, but permit functional assays, as well as evaluation of CTC-derived DNA, RNA and proteins, including single-cell analysis. Blood biopsies are less invasive than tissue biopsies and hence amenable to serial collection, which can provide critical molecular information in real time. In conclusion, liquid biopsy is a powerful tool, and remarkable advances in this technology have impacted multiple aspects of precision oncology, from early diagnosis to management of refractory metastatic disease. Future research may focus on fluids beyond blood, such as ascites, effusions, urine, and cerebrospinal fluid, as well as methylation patterns and elements such as exosomes.